Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Populus alba pollen is an allergenic extract derived from the pollen of the Populus alba plant, also known as the white poplar tree. It is a biological product used for both diagnostic and therapeutic purposes in individuals with allergies to tree pollens. For diagnosis, it is used in allergy skin tests. As a therapy, it is administered via immunotherapy (hyposensitization) to gradually build tolerance to the allergen, thereby reducing the allergic response. The product is available as a non-standardized injectable solution and is marketed by several companies, including ALK-Abello and Greer Laboratories. It has been in use since 1965 for patients with immediate hypersensitivity to white poplar pollen and related allergens. [1, 2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Populus alba pollen.